Mr. Eli Ben Haroosh reports

ZERO CANDIDA SCALES PRODUCTION TO 250 ISO 13485 CLINICAL-GRADE PROTOTYPES OF ZC-001 THERAPEUTIC DEVICE

Zero Candida Technologies Inc. is scaling manufacturing to 250 clinical-grade prototypes of its ZC-001 therapeutic device under ISO 13485-certified quality standards.

This production milestone is a strategic step forward in the company's regulatory road map, supporting further preclinical testing under good laboratory practice standards and remaining on track to initiate a targeted clinical study involving at least 100 women in fourth quarter 2026. The planned study will further evaluate efficacy, building upon prior laboratory testing demonstrating 99.999-per-cent fungal eradication under controlled conditions.

Completion of the 250 units is expected within 90 days.

"Scaling volume helps us transition from laboratory validation to human studies more efficiently and demonstrates our commitment to medical-grade excellence," said Eli Ben-Haroosh, chief executive officer of Zero Candida. "We look forward to sharing updates as we advance on our 2026 road map to bring innovative solutions to women worldwide living with recurrent VVC."

ZC-001 is a smart, artificial-intelligence-enabled therapeutic device integrating precision blue light therapy, targeted drug delivery and wireless diagnostics for personalized at-home treatment of vulvovaginal candidiasis. The device is designed to improve outcomes in recurrent and drug-resistant infections while reducing the need for repeated in-clinic visits. Its underlying technology may support future applications across other areas of women's health.

About Zero Candida Technologies Inc.

Zero Candida is a publicly traded femtech company pioneering innovative solutions to address unmet needs in women's health. The company is developing a smart, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat vulvovaginal candidiasis through personalized, at-home care. This condition affects approximately 75 per cent of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. With the VVC treatment market projected to exceed $2-billion (U.S.) by 2030, Zero Candida is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century.

We seek Safe Harbor.